News

On May 2, 2015 Bill and Kim Procko will be hosting a skateboarding competition “Carve to CureDuchenne,” which is intended to benefit the nonprofit CureDuchenne organization that funds research projects hoping to find a cure for Duchenne muscular dystrophy and raises awareness about the disease. The fundraising event will take place at…

aTyr Pharma (“aTyr”), a biotherapeutics company involved in the discovery and clinical development of pioneering medicines for patients with severe rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulator, recently announced that Resolaris has been granted Orphan Drug Designation by the U.S.

BioMarin Pharmaceutical Inc., a company that develops and commercializes biopharmaceuticals for serious diseases and medical conditions, recently announced conclusion of the continuing proposal of a New Drug Application (NDA) to the FDA for drisapersen, an investigational exon-skipping drug candidate aimed at treating the largest genetically defined subset of…

For most of us, using a smartphone is pretty intuitive, simply requiring touch input on the display to operate the device. However, for persons with disabilities of the upper extremities that cause difficulty using their hands and fingers, smartphones are considerably less simple to manipulate. Samsung Electronics has recently announced…

Clinical-stage biotechnology company Capricor Therapeutics, Inc. was recently awarded orphan drug designation for its investigational cell therapy CAP-1002, from the U.S. Food and Drug Administration (FDA). The agency granted the status to the company, which is working on the development of CAP-1002 to treat …

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company that develops novel drugs to treat diabetes and cardiovascular dysfunction in patients suffering from rare diseases, recently announced positive data from a pre-clinical study for the use of PB-1046 in Duchenne Muscular Dystrophy (DMD) mice models. The results were presented in…

Santhera Pharmaceuticals announced in a press release that an international team of researchers recently published in the journal The Lancet the results of the DELOS Phase 3 trial validating the efficacy and safety of Santhera’s Raxone/Catena (idebenone) in patients with Duchenne muscular dystrophy (DMD). The study…

Japan’s Cyberdyne, Inc. has applied for marketing authorization of their HAL for Medical Use (Lower Limb Type) robot exoskeleton as a new medical device for orphan neural-muscular diseases, such as muscular dystrophy, amyotrophic lateral sclerosis (ALS) and others under Japan’s Pharmaceutical and Medical Device Law (PMDL). Under the law,…

Toronto will come together on Saturday, May 2nd, to make muscles move against muscular dystrophy. Thousands of people suffering with any kind of neuromuscular disorder in Canada will be supported by the community at the annual Toronto Walk for Muscular Dystrophy. Mayyan Ziv, who is the 2015 Toronto Walk Ambassador, strongly believes in the…

GlobalData recently reported that the global treatment market for Duchenne Muscular Dystrophy will expand in value at a staggering Compound Annual Growth Rate (CAGR) of 160.5%, from about $8.2 million in 2014 to $990 million by 2019. In the latest report, OpportunityAnalyzer: Duchenne Muscular Dystrophy – Opportunity and Market Analysis…